Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Study on the mechanism of glycyrrhizic acid attenuating gefitinib-induced hepatotoxicity in mice

ABSTRACT: To study the hepatotoxic effects of gefitinib in mice and to explore the mechanism of action of glycyrrhetinic acid in attenuating gefitinib hepatotoxicity.

ORGANISM(S): Mus musculus

PROVIDER: GSE226800 | GEO | 2023/03/08

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

A pumpless liver-on-a-chip for drug hepatotoxicity analysis

Project description:This study presents the development and validation of an innovative microfluidic liver-on-a-chip device utilizing gravity-driven perfusion for the evaluation of drug hepatotoxicity. This research involved the construction of a hydrogel-based coculture chip that integrates liver parenchymal and stellate cells within a tri-channel configuration. The assembly and operation of the liver-on-a-chip and its accompanying custom rocker were straightforward. The chip maintained high cell viability and continuous liver albumin synthesis over extended culture durations. Acetaminophen, a hepatic injury-inducing drug, was utilized as a positive control in hepatic toxicity assays on the chip. The liver chip exhibited hepatotoxic responses comparable to those observed in 2D models. Furthermore, in this study we evaluated the effects of two plant-derived natural compounds, aristolochic acid I (AA) and its ana-log aristolactam AII (AL), in both 2D cell models and the liver-on-a-chip system. Aristolochic acid I, known for its hepatorenal toxicity, was observed to cause hepatotoxicity in both the 2D models and on the chip. Flow cytometry and mRNA sequencing results confirmed the propensity of these compounds to induce liver cell apoptosis. Notably, aristolactam AII, previously consid-ered nontoxic, provoked a significant decrease in the hepatic functionality marker albumin exclusively in the liver chip but not in 2D models, indicating the liver chip's enhanced sensitivity to toxic substances. In summary, this pumpless liver-on-a-chip offers a simple yet powerful tool for drug hepatotoxicity studies.

2024-01-02 | GSE252399 | GEO

Analysis of gene expression change by gefitinib treatment in gefitinib sensitive PC9 and resistant PC9.

2012-07-01 | GSE38302 | GEO

Analysis of gene expression change by gefitinib treatment in gefitinib sensitive PC9 and resistant PC9.

Project description:We established a gefitinib-resistant cell line (PC-9GR), by serial exposure of gefitinib to PC-9, an originally gefitinib-sensitive lung cancer cell line (PC-9na), for long period.We collected total RNA from both PC-9 and PC-9GR and examined mRNA expression profile, comprehensively. Gefitinib induced gene expression was measured in human lung cancer cell line was measured at 48 hours after exposure to 1uM Gefitinib.

2012-06-30 | E-GEOD-38302 | biostudies-arrayexpress

miRNA expression of gefitinib-resistant cell lines

Project description:To identify novel miRNAs involved in acquired EGFR TKI resistance in NSCLC, genome-wide miRNA expression analysis was performed in gefitinib-resistant sub-cell lines and gefitinib-sensitive parental cell lines.

2018-02-21 | GSE110815 | GEO

Gefitinib sensitivity in NSCLC cell lines

Project description:Eleven NSCLC cell lines with widely divergent gefitinib sensitivities were compared using gene expression. Genes associated with gefitinib response were used to classify additional NSCLC lines with unknown gefitnib sensitivity. A subset of the test set data was tested for gefitinib sensitivity, and results correlated strongly with the gene expression-based predictions All eleven training set lines, and seven test set lines had both HGU133A and B chips done, while other test set lines had only HGU133As. Keywords: cell response comparison

2006-08-31 | GSE4342 | GEO

Human Non-Small Cell Lung Cancer cells: Control vs gefitinib treated cells

Project description:Total gene expression difference after treatment gefitinib for 24 h compared to control NSCLCs To determine which proteins are responsible for the differences in glutamine metabolism in response to the gefitinib treatment between gefitinib-sensitive and gefitinib-resistant cells

2017-09-13 | GSE103780 | GEO

Toxicogenomic profiling in the whole zebrafish embryo after exposure to reference hepatotoxicants.

Project description:Zebrafish embryos have been proposed as an attractive alternative model system for hepatotoxicity testing. In this study we determined gene expression responses after exposure to reference hepatotoxicants and controls to identify biomarkers for hepatotoxicity. 188 samples; hepatotoxic compounds at 3 concentrations and with multiple replicates; negative controls at single concentration and with multiple replicates; water (DSW) and 0.2% DMSO vehicle control.

2014-12-16 | E-GEOD-55618 | biostudies-arrayexpress

Compound kushen injection and YFSJ reduce gefitinib resistance in gefitinib resistant lung cancer cell lines

Project description:Compound Kushen Injection (CKI) has been used in clinics for nearly 20 years to treat different kinds of cancers. In this study, we found that CKI inhibited gefitinib resistant cell line proliferation, reduced drug resistance and improved anti-cancer effects when associated with gefitinib in a dose-dependent fashion. We also identified candidate CKI associated molecular mechanisms that might reduce drug resistance using transcriptome analysis methods, including gene differential expression analysis and pathway over-representation analysis. Multiple pathways were perturbed and the PI3K/AKT/MTOR and autophagy pathways were identified as the potential primary target pathways of CKI in this context. We also investigated the molecular mechanisms of another TCM, Yifei-Sanjie Wan (YFSJ) on reducing gefitinib resistance using transcriptome analysis.

2022-01-15 | GSE125933 | GEO

Gefitinib treatment in human EGFR-driven-Gefitinib resistant tumoral cell line

Project description:Gefitinib treatment in human EGFR-driven-Gefitinib resistant tumoral cell line

| PRJNA483409 | ENA

The lncRNAs, circRNAs and mRNAs involved in gefitinib-resistance of PC9 cells

Project description:In this study, we established an gefitinib resistant lung adenocarcinoma cell line (i.e. PC9/GR) from lung adenocarcinoma PC9 cell line which was sensitive to gefitinib. Then microarray was performed to elucidate the lncRNAs, cirRNAs and mRNAs involved in gefitinib resistance.

2022-04-11 | GSE169513 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data